2-(2-氨基-2-氧代乙氧基)苯甲酸 | 56424-81-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(2-氨基-2-氧代乙氧基)苯甲酸
• 英文名称: 2-carbamoylmethoxy-benzoic acid
• 英文别名: 2-Carboxy-phenoxyessigsaeure-amid；2-Carbamoylmethoxy-benzoesaeure；Salicylsaeure-O-essigsaeureamid；2-(2-Amino-2-oxoethoxy)benzoic acid
• CAS: 56424-81-8
• 化学式: C₉H₉NO₄
• mdl: MFCD04508187
• 分子量: 195.175
• InChiKey: UKHQVRKUAZGYQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  89.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  2-(2-氨基-2-氧代乙氧基)苯甲酸 、 5-{[(3R)-piperidin-3-yl]methoxy}-2-(1H-pyrazol-5-yl)pyridine 在 propylphosphonic anhydride 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 2-[2-[(3R)-3-[[6-(1H-pyrazol-5-yl)pyridin-3-yl]oxymethyl]piperidine-1-carbonyl]phenoxy]acetamide
  参考文献：
  名称：

  EP3418276

  摘要：

  公开号：
• 作为产物：
  描述：

  水杨酸 、 氯乙酰胺 在 potassium carbonate 、 potassium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 2-(2-氨基-2-氧代乙氧基)苯甲酸
  参考文献：
  名称：

  Synthesis and Biological Evaluation of 2-Phenoxyacetamide Analogues, a Novel Class of Potent and Selective Monoamine Oxidase Inhibitors

  摘要：

  单胺氧化酶（EC 1.4.3.4；MAOs）是一类含有FAD的酶，是抗抑郁药物的重要靶点。本文中，合成了一系列2-苯氧乙酰胺类似物，并使用酶和癌细胞裂解液评估了它们对单胺氧化酶A（MAO-A）和B（MAO-B）的抑制活性。成功鉴定出2-（4-甲氧基苯氧基）乙酰胺（化合物12）（SI = 245）和2-（4-（（丙-2-炔基亚氨基）甲基）苯氧基）乙酰胺（化合物21）（IC50MAO-A = 0.018 μM，IC50MAO-B = 0.07 μM）分别作为最特异的MAO-A抑制剂和最强的MAO-A/-B抑制剂。还利用HepG2和SHSY-5Y细胞裂解液进一步评估了这两种化合物在活细胞中的抑制活性。

  DOI：

  10.3390/molecules191118620

文献信息

• [EN] TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS<br/>[FR] INHIBITEURS DE PRMT5 DÉRIVÉS DE TÉTRAHYDROISOQUINOLÉINE
  申请人：CTXT PTY LTD

  公开号：WO2016034673A1

  公开（公告）日：2016-03-10

  A compound of formula I wherein: n is 1 or 2: p is 0 or 1; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (i) optionally substituted phenyl; (ii) optionally substituted naphthyl; or (iii) optionally substituted C5-12 heteroaryl.

  式I的化合物，其中：n为1或2；p为0或1；R1可选地为一个或多个卤素或甲基基团；R2a和R2b分别选自以下组：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R2c和R2d分别选自以下组：(i) F；(ii) H；(iii) Me；和(iv) CH2OH；R3a和R3b分别选自H和Me；R4为H或Me；R5为H或Me；R6a和R6b分别选自H和Me；A为(i)可选地取代的苯基；(ii)可选地取代的萘基；或(iii)可选地取代的C5-12杂环基。
• Beta-alanine derivatives and their use as receptor anatgonists
  申请人：——

  公开号：US20030018193A1

  公开（公告）日：2003-01-23

  A beta-alanine derivative of the formula (I) wherein R 1 is hydrogen atom or an amino protective group; A is a lower alkylene group or a lower alkenylene group; R 2 is hydrogen atom or an amino group which may be substituted with an acyl group; R 3 is hydrogen atom or an aryl or aralkyl group which may be substituted with one or more of hydroxy and/or lower alkoxy, a moiety represented by the formula (II), which is a bivalent N-containing 6- to 8-membered heterocyclic group, or a pharmaceutically acceptable salt thereof.

  公式（I）的β-丙氨酸衍生物，其中R1是氢原子或氨基保护基团；A是较低的烷基或较低的烯基基团；R2是氢原子或氨基团，可能被酰基取代；R3是氢原子或芳基或芳基基团，可能被一个或多个羟基和/或较低的烷氧基取代，由公式（II）表示的基团，该基团是一种双价的含氮6-到8-成员杂环基团，或其药用盐。
• ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS
  申请人：Yamagishi Tatsuya

  公开号：US20120232052A1

  公开（公告）日：2012-09-13

  The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar 1 is phenyl; Ar 2 is aryl; n is 1-4; X is —O—, —S—, —SO— or —SO 2 —, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of such disorders and diseases as pain in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases as pain in which voltage gated sodium channels are involved.

  本发明涉及公式（I）的芳基羧酰胺衍生物，其中Ar1是苯基；Ar2是芳基；n为1-4；X为—O—、—S—、—SO—或—SO2—，其前体药物或其药学上可接受的盐，具有阻断电压门控钠通道如TTX-S通道的活性，并在治疗或预防涉及电压门控钠通道的疾病和疾病，如疼痛方面中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病和疾病，如疼痛方面的使用。
• GSK6853, a Chemical Probe for Inhibition of the BRPF1 Bromodomain
  作者：Paul Bamborough、Heather A. Barnett、Isabelle Becher、Mark J. Bird、Chun-wa Chung、Peter D. Craggs、Emmanuel H. Demont、Hawa Diallo、David J. Fallon、Laurie J. Gordon、Paola Grandi、Clare I. Hobbs、Edward Hooper-Greenhill、Emma J. Jones、Robert P. Law、Armelle Le Gall、David Lugo、Anne-Marie Michon、Darren J. Mitchell、Rab K. Prinjha、Robert J. Sheppard、Allan J. B. Watson、Robert J. Watson

  DOI：10.1021/acsmedchemlett.6b00092

  日期：2016.6.9

  The BRPF (Bromodomain and PHD Finger-containing) protein family are important scaffolding proteins for assembly of MYST histone acetyltransferase complexes. A selective benzimidazolone BRPF1 inhibitor showing micro molar activity in a cellular target engagement assay was recently described. Herein, we report the optimization of this series leading to the identification of a superior BRPF1 inhibitor suitable for in vivo studies.
• BETA-ALANINE DERIVATIVES AND THEIR USE AS RECEPTOR ANTAGONISTS
  申请人：FUJISAWA PHARMACEUTICAL CO., LTD.

  公开号：EP1255748A1

  公开（公告）日：2002-11-13